Blockchain Registration Transaction Record

NRx Re-files FDA Application for Safer Ketamine Amid Drug Shortage

NRx Pharmaceuticals re-files FDA application for preservative-free ketamine KETAFREE™ amid drug shortage. Safer alternative targets $750M US market, addresses neurotoxicity concerns.

This development matters because ketamine has emerged as a crucial treatment for severe depression and other mental health conditions, particularly for patients who haven't responded to traditional antidepressants. The current drug shortage creates significant barriers to care for vulnerable populations, while safety concerns about existing formulations have limited broader adoption. A preservative-free option could expand treatment access, reduce side effects, and potentially save lives among patients with treatment-resistant depression and suicidal ideation. As mental health crises continue to rise globally, safer and more accessible ketamine treatments represent an important advancement in psychiatric care.